Publication details

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

Authors

ZLÁMALÍKOVÁ Lenka MOULIS Mojmír RAVČUKOVÁ Barbora LIŠKOVÁ Květoslava MALČÍKOVÁ Jitka ŠÁLEK David JARKOVSKÝ Jiří SVITÁKOVÁ Miluše HRABÁLKOVÁ Renata ŠMARDA Jan ŠMARDOVÁ Jana

Year of publication 2017
Type Article in Periodical
Magazine / Source Oncology Reports
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.spandidos-publications.com/10.3892/or.2017.5891
Doi http://dx.doi.org/10.3892/or.2017.5891
Field Oncology and hematology
Keywords mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation
Description Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.
Related projects: